Halozyme scores $63M drug delivery deal

Halozyme has inked another pact for rHuPH20, an enzyme designed to spur the absorption of certain injectables. This $63 million deal--$9 million upfront and $54 million in milestones--gives Intrexon the right to use the enzyme technology with its therapy for a rare genetic disorder. Halozyme inked a similar $83 million deal last month with ViroPharma. "The combination of Intrexon's synthetic DNA platform for high-level A1AT production with Halozyme's subcutaneous enzyme technology may enable the first recombinant human A1AT replacement therapy with a more patient-friendly administration profile," said Halozyme CEO Gregory Frost. Release

Suggested Articles

After beating the standard of care at keeping testosterone levels down, Myovant's prostate cancer drug fell short in patients with metastatic disease.

A Mount Sinai-led team found that immune cells in the brain protect it from abnormal activation that can lead to behavioral problems.

Results from the small cohort suggest the vaccine triggers comparable immune responses in younger and older adults.